Nutritional outcomes in cystic fibrosis - are we doing enough?y

被引:8
作者
Connett, Gary J. [1 ,2 ]
Pike, Katharine C. [3 ]
机构
[1] Southampton Childrens Hosp, Southampton SO16 6YD, Hants, England
[2] UK Natl Inst Hlth Res, Southampton Resp Biomed Res Unit, Southampton SO16 6YD, Hants, England
[3] UCL, Inst Child Hlth, London WC1N 1EH, England
关键词
Cystic Fibrosis; Nutrition; Body Mass Index; Lean Body Mass; Adherence; PULMONARY-FUNCTION; BODY-COMPOSITION; CHILDREN; THERAPY; SURVIVAL;
D O I
10.1016/j.prrv.2015.07.015
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Although outcome data for individuals with cystic fibrosis (CF) have shown consistent improvements throughout the twentieth century, more recent national registry data suggests that outcomes have reached a plateau. Median values for nutritional outcomes in CF currently cluster around the fiftieth centile for the normal population. These data suggest that up to half of CF patients have sub-optimal body mass index (BMI) which might have a significant adverse impact on their respiratory status. BMI might be underestimating the extent to which more important lean body mass might also be reduced. Nutritional decline is a particular problem during adolescence and commonly persists into early adult life. Current treatment strategies to optimize nutrition include the use of high energy diets, proton pump inhibitors and optimal use of enzyme preparations including higher strength preparations to decrease pill burden. Whilst these are all of potential benefit, poor adherence to nutritional care recommendations is probably the greatest impediment to future health improvement. More effective strategies to impact on treatment adherence are needed. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 21 条
[1]  
[Anonymous], J CYSTIC FIBROSIS S2
[2]  
[Anonymous], 2010, CYSTIC FIBROSIS FDN
[3]   An Evidence-Based Review of Treatment-Related Determinants of Patients' Nonadherence to HIV Medications [J].
Atkinson, Mark J. ;
Petrozzino, Jeffrey J. .
AIDS PATIENT CARE AND STDS, 2009, 23 (11) :903-914
[4]   Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis [J].
DiMango, Emily ;
Walker, Patricia ;
Keating, Claire ;
Berdella, Maria ;
Robinson, Newell ;
Langfelder-Schwind, Elinor ;
Levy, Diane ;
Liu, Xinhua .
BMC PULMONARY MEDICINE, 2014, 14
[5]   Cystic fibrosis mortality and survival in the UK: 1947-2003 [J].
Dodge, J. A. ;
Lewis, P. A. ;
Stanton, M. ;
Wilsher, J. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (03) :522-526
[6]   Nutrition and survival in cystic fibrosis [J].
Elborn, JS ;
Bell, SC .
THORAX, 1996, 51 (10) :971-972
[7]   Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies [J].
Eom, Chun-Sick ;
Park, Sang Min ;
Myung, Seung-Kwon ;
Yun, Jae Moon ;
Ahn, Jeong-Soo .
ANNALS OF FAMILY MEDICINE, 2011, 9 (03) :257-267
[8]  
Giuliano C, 2012, EXPERT REV CLIN PHAR, V5, P337, DOI [10.1586/ecp.12.20, 10.1586/ECP.12.20]
[9]   Pancreatic Enzyme Replacement Therapy Dosing and Nutritional Outcomes in Children with Cystic Fibrosis [J].
Haupt, Mark E. ;
Kwasny, Mary J. ;
Schechter, Michael S. ;
McColley, Susanna A. .
JOURNAL OF PEDIATRICS, 2014, 164 (05) :1110-+
[10]   Overweight and obesity in ΔF508 homozygous cystic fibrosis [J].
Kastner-Cole, D ;
Palmer, CNA ;
Ogston, SA ;
Mehta, A ;
Mukhopadhyay, S .
JOURNAL OF PEDIATRICS, 2005, 147 (03) :402-404